Kornimate/medical-research-clean huggingface dataset:
algorithms to diagnose pulmonary arterial hypertension

Conditions: Pulmonary Arterial Hypertension

Summary: the investigators intend to evalute the value of radiomics signature of pulmonary vessels from chest computed tomography (ct) for dianosis and prognosis of pulmonary arterial hypertension.

pulmonary arterial hypertension (pah) is a heterogeneous disorder composed of varying pathobiology that may involve multiple clinical conditions. computed tomography (ct) is a minimally invasive imaging technique capable of providing both high contrast and high resolution detail of the lungs and arteries. application of radiomics as prognosis and diagnosis tools could quantifies high-dimensional features from ct data to investigate vescualr heterogeneity.development and validation of pah diagnosis algorithms based on radiomics may serve as a complementary readout to current ct-based metrics and provide valuable evidence to make the treatment management decision in early pah.

Eligibility criteria:
inclusion criteria: 1. chest ct examination and cardiac ultrasound examination were performed within 3 months before and after right heart catheterization; 2. mpap \> 25mmhg and pvr\< 3woods (measured by right heart catheter) and pulmonary vascular resistance was collected as pah group whereas healthy volunteers as non-pah control group in developement corhort; 3. spap \> 36mmhg (measured by echocardiography) was collected in validation corhort. exclusion criteria: 1.cancer; 2. the quality of chest ct and cardiac ultrasound images is poor; 3.pulmonary vascular segmentation is affected by thoracic organ displacement or pulmonary vascular complete occlusion due to diseases ,such as spinal deformity.

Keywords: pulmonary arterial hypertension diagnosis model prediction algorithm
mycophenolate mofetil in patients with progressive idiopathic membranous nephropathy

Conditions: Glomerulonephritis, Membranous

Summary: cyclosporin decreases proteinuria and improve renal function in patients with idiopathic membranous nephropathy, but has a risk of side effects such as nephrotoxicity. the investigators plan to the study to evaluate whether mycophenolate mofetil (mmf) could be a reasonable alternative with fewer side effect.

idiopathic membranous nephropathy is most common cause of glomerulonephritis in adults. persistent high grade proteinuria or progressively decrease of renal function is a risk factor for end stage renal disease in idiopathic membranous nephropathy. it has been reported that cyclosporin in patients with idiopathic membranous nephropathy decreases proteinuria and improve renal function. mycophenolate mofetil is a recently developed immunosuppressive agent with fewer side effect than cyclosporin. in this study patients with high risk group of progressive idiopathic membranous nephropathy will be treated with mycophenolate mofetil and low dose prednisone. the outcome will be compared to controls treated with cyclosporin and low dose prednisone.

Eligibility criteria:
inclusion criteria: 1. patients with idiopathic membranous nephropathy 2. the duration of disease is less than twelve months 3. patients with persistent proteinuria more than 8 grams per day 4. patients who provided informed consent 5. the cases that satisfy more than three of following items even if proteinuria is less than 8 grams per day: * egfr \< 60 ml/min/1.73m2 * hypertension (bp above 140/90mmhg or bp above 120/80 in patients taking anti-hypertensive agents) * 24 hours urine protein or spot urine protein/creatinine ratio \> 5.0 g/day * serum albumin (g/dl) \< 3.0 * selectivity index \> 0.2 exclusion criteria: 1. severe digestive organ disease 2. allergy history to clinical trial medication and acute or chronic allergy for 4 weeks recently. 3. clinical history of treatment with other immunosuppressive medication 4. probability of pregnancy, breast feeding woman 5. uncontrolled hypertension (more than 160/100mmhg) 6. uncontrolled systemic disease 7. drug addiction or alcoholics within 6 months 8. egfr is less than 30ml/min at screening 9. abnormal liver function test (more than 3 times above compared with normal value) 10. absolute neutrophil count \<1,500/mm3 or leukocyte \<2,500/mm3 or platelets \<100,000/mm3 11. secondary membranous nephropathy 12. expected life expectancy is less than 1 year

Keywords: idiopathic membranous nephropathy mycophenolate mofetil proteinuria renal function
idarubicin based combined modality therapy in primary cns lymphoma

Conditions: Primary Central Nervous System Lymphoma

Summary: idarubicin combined with high dose methotrexate and moderate dose radiotherapy will achieve similar survival outcomes but with reduced neurotoxicity compared to regimens using methotrexate with high dose radiotherapy.

combined modality therapy in pcnsl has improved survival outcomes but at the cost of unacceptable rates of neurotoxicity when high dose radiotherapy is used. idarubicin has activity in systemic lymphomas and crosses the blood brain barrier and may add to the efficacy of methotrexate. by combining these 2 drugs with moderate dose radiotherapy survival outcomes should be optimal but with lower rates of neurotoxicity. comparison: trog has previously performed a phase 2 study using methotrexate with high dose radiotherapy and this will allow comparison of survival and neurotoxicity rates.

Eligibility criteria:
inclusion criteria: * histologically proven primary cns lymphoma. * absence of disease outside the cns. * ecog performance status 0-3 * negative hiv status. * peripheral blood counts with granulocytes \>1.5 x 109l and platelets \> 100 x 109l. serum creatinine \<150mmol/l. serum bilirubin \<1.5 times and ast \<2 times upper limit of normal. * age \>18 and \<=70 years. * patients must give written informed consent. * corticosteroids prior to histological diagnosis are allowed. exclusion criteria: * previous history of malignancy (other than non-melanomatous skin carcinoma, or carcinoma in situ of cervix completely excised). * patients who are pregnant or lactating. * nyha (new york state heart association classification) cardiac failure grade 3 * macroscopic spinal thecal or spinal cord disease.

Keywords: lymphoma pcnsl primary cns lymphoma
effect of progressive early mobilization in patients with tbi

Conditions: Early Waking; Trauma; ICU Acquired Weakness

Summary: traumatic brain injury (tbi) is a major public health concern worldwide. patients with moderate-severe tbi have high rates of disability at the acute phase and frequently require protracted rehabilitation with prolonged periods of recovery. recently, it has been found that the use of progressive early mobilization (em) protocols for critical trauma patients may minimize the functional declines during intensive care unit (icu) stays. however, prior early mobilization studies have found that the survivors of moderate-severe tbi often experience a greater incidence of neurological injuries with other organ injury than other critical care patients. no randomized controlled trials thus far have utilized measure the influence or effect of early progressive em protocols on the functional recovery of moderate-severe tbi patients.

objective: the goals of this proposed research study are (1) to investigate the feasibility of using a structured progressive em protocol for patients with moderate-severe tbi in a trauma icu and (2) the goal is to investigate and compare the intervention effects of a progressive em protocol (aimed at bringing patients at least to the mobility level-3 of sitting on the edge of bed) in an icu on short-term and long-term functional abilities in patients with moderate-severe tbi.

Eligibility criteria:
inclusion criteria: * expected to stay for at least 72 hours in the icu, * \>20 years of age with living independently before the onset of critical illness * relatively stable vital signs with a glasgow coma scale (gcs) score of ≥6 * relatively stable respiratory status (spo2 \>92%, high mechanical ventilator setting: fio2 ≤60%, and positive end-expiratory pressure ≤10 cmh2o) * stable cardiovascular system (resting heart rate ≤130 bpm or no use of high-dose vasopressor of more than 0.2 μg kg-1 min-1) exclusion criteria: * predicted mortality within the next 24 hours * palliative care * consistent increase of intracranial pressure (\>20 mmhg) * pregnancy * uncontrolled seizure * active bleeding * ruptured or leaking aortic aneurysm * development of acute myocardial infarction during icu stay * rapid development of degenerative neuromuscular diseases * contraindication for early walking
the metabolic effects of empagliflozin in patients with high risk of heart failure

Conditions: Obesity; Heart Failure

Summary: the aim of this trial is to assess the effect of empagliflozin on lipid and glucose metabolism as well as volume homeostasis and renal function in elderly and obese patients with increased risk of developing heart failure. no history of established heart failure or diabetes is allowed. the primary hypotheses are that 6 months treatment with empagliflozin 10 mg a day will: 1) decrease epicardial adipose tissue volume, and 2) reduce estimated extracellular volume compared with placebo.

the empire prevent: metabolic is a part of the empire prevent trial program, which also comprises the empire prevent: cardiac. the empire prevent: metabolic is designed to enroll at least 120 patients.

Eligibility criteria:
inclusion criteria: * body mass index \>28kg/m2 * age 60-84 years * established risk factor for developing heart failure, defined as at least one of the following: * hypertension * ischemic heart disease * stroke/transient cerebral ischemia * chronic kidney disease (egfr 30-45ml/min/1.73m2) exclusion criteria: * diabetes mellitus type 1 or 2 (no medical history, no antidiabetic treatment) * heart failure with reduced ejection fraction (lvef \<40%) * inability to perform exercise test * dementia * severe non-compliance * substance abuse * severe chronic obstructive pulmonary disease (fev1\<50% expected value) * permanent atrial fibrillation * gfr \<30 ml/min/1,73m2 * severe peripheral artery disease * cancer treatment within one year beside prostate cancer and basal cell carcinoma * severe aortic or mitral valve disease * pregnancy or breastfeeding * acute hospital admission within 30 days * participation in other pharmacological study

Keywords: renal function glucose intolerance lipid metabolism
identification of prognostic urinary biomarker for acute kidney injury in preterm infants by proteomics

Conditions: Acute Kidney Injury

Summary: clinical definitions of acute kidney injury (aki) have been based on an increase in serum creatinine and a decrease in urine output. however, applying this definition to neonates remains challenging because of the normal renal physiologic features that serum creatinine levels are expected to increase in the first days after birth, and impaired sodium reabsorption and concentrating ability. because of several limitations of early detection of aki, investigators are focused on identifying biomarkers that predict aki before an increase serum creatinine level. investigators will collect urine from preterm infants before and after administrating ibuprofen for closing patent ductus arteriosus. to identify novel biomarkers, investigators will analyze urine by proteomics. to verify those biomarkers, investigators will use initial urine on the first day of life from preterm infants who diagnosed aki within 7 days after birth without any risk factors for aki and enrolled institutional bio-repository.


Eligibility criteria:
inclusion criteria: * preterm infants less than 32 weeks gestational age or birth weight less than 1,500 g admitted to the neonatal intensive care unit at seoul national university children's hospital exclusion criteria: * congenital heart disease * known major congenital anomalies of the kidney and urinary tract * other genetic syndromes or medical conditions that preclude enrollment per judgement of the attending neonatologist
a study comparing tretinoin cream 0.025% and retin-a® cream 0.025% in the treatment of acne vulgaris

Conditions: Acne Vulgaris

Summary: the bioequivalence and safety of tretinoin cream 0.025% (taro pharmaceuticals u.s.a, inc.) and retin-a® (tretinoin) cream 0.025% in the treatment of acne vulgaris.

a multi-center, double-blind, randomized, placebo controlled, parallel-group study, comparing tretinoin cream 0.025% (taro pharmaceuticals u.s.a) and retin-a® (tretinoin) cream 0.025% and both active treatment to a placebo control in the treatment of acne vulgaris

Eligibility criteria:
inclusion criteria: * healthy male or non-pregnant female aged ≥ 12 and ≤ 40 years with a clinical diagnosis of acne vulgaris. * subjects who are 18 years of age or older (up to the age of 40) must have provided irb approved written informed consent. subjects 12 to 17 years of age, inclusive, must have provided irb approved written assent * subjects must have a definite clinical diagnosis of acne vulgaris severity grade 2, 3, or 4 as per the investigator's global assessment (iga) exclusion criteria: * female subjects who are pregnant, nursing or planning to become pregnant during study participation * subjects with a history of hypersensitivity or allergy to tretinoin, retinoids, or any of the study medication ingredients. * subjects with the presence of any skin condition that would interfere with the diagnosis or assessment of acne vulgaris (e.g., on the face: rosacea, dermatitis, psoriasis, squamous cell carcinoma, eczema, acneiform eruptions caused by medications, steroid acne, steroid folliculitis, or bacterial folliculitis).
effects of humidified ventilation on arterial oxygenation and respiratory mechanics during one lung ventilation

Conditions: Lung Cancer

Summary: a continuous loss of moisture and heat occurs during mechanical ventilation and prediposes patients to airway damage. vaporizing humidifier has known to be advantages of improvement of oxygenation and protection of airway damage. however, there is a lack of study about the effect of humidified ventilation on oxygenation and respiratory mechanics during one-lung ventilation. we therefore invesgate that the effect of humidified ventilation on oxygenation and respiratory mechanics during one-lung ventilation .


Eligibility criteria:
inclusion criteria: * asa physical status class i,ii * unilateral lung lobectomy * use of one-lung ventilation exclusion criteria: * copd * caod * unstable cardiovascular status * peak inspiratory pressure \> 30 mmhg

Keywords: lung cancer
european registry of type a aortic dissection

Conditions: Type A Aortic Dissection

Summary: acute stanford type a aortic dissection (taad) is a life-threatening condition. surgery is usually performed as a salvage procedure and is associated with significant postoperative early mortality and morbidity. understanding the patient's conditions and treatment strategies which are associated with these adverse events is essential for an appropriate management of acute taad.

twenty centers from eight european centers of cardiac surgery have collaborated to create a multicentre observational registry (ertaad), which will enroll consecutive patients who underwent surgery for acute taad from january 2005 to march 2021. the investigators will compare patient's comorbidities, condition at referral, surgical strategies and perioperative treatments in patients with and without early and late adverse events. the primary clinical outcome will be in-hospital mortality, late mortality and reoperations on the aorta. secondary outcomes will be stroke, acute kidney injury, surgical site infection, reoperation for bleeding, transfusion of blood products and length of stay in the intensive care unit.

Eligibility criteria:
inclusion criteria: * type a aortic dissection or intramural hematoma involving the aortic root/ascending aorta; * patients aged \> 18 years: * symptoms started within 7 days from surgery; * primary surgical repair of acute type a aortic dissection; * any other major cardiac surgical procedure concomitant with surgery for type a aortic dissection. exclusion criteria: * patients aged \< 18 years; * onset of symptoms \> 7 days from surgery; * prior procedure for type a aortic dissection; * retrograde type a aortic dissection (with primary tear located in the descending aorta); * concomitant endocarditis; * type a aortic dissection secondary to blunt or penetrating chest trauma.

Keywords: aortic dissection
treatment of small acute cuff tears, a randomized study

Conditions: Rotator Cuff Tear

Summary: the purpose of this project is to compare operative repair of traumatically torn rotator cuff tendon with physiotherapy in a randomized prospective study.

in clinical practice most patients with a traumatic acute rotator cuff tear are treated with operative repair. the results of surgery are in most cases good but there are also good results in the literature from conservative treatment. so far there has been no prospective randomized comparison between the two treatments. when it comes to degenerative non-traumatic tears, level 1 and 2 studies have not been able to show the superiority of surgery. this study takes place in 2 clinics in sweden (linköping and kalmar). patients who have no previous shoulder conditions, a trauma to the shoulder and pain and/or inability to lift their arm will undergo magnetic resonance imaging (mri). if this indicates a full-thickness rotator cuff tear of the cranial part of the rotator cuff the patient will be randomized to surgery or physiotherapy. surgical intervention is mini-open repair. follow-up takes place at 3 months, 6 months and 12 months with patient scores taken by a blinded independent physiotherapist. at 12 months a new mri is conducted as well.

Eligibility criteria:
inclusion criteria: * trauma to the shoulder * full thickness cranial rotator cuff tear * operation possible within 3 months exclusion criteria: * 2 or more rotator cuff tendons involved * fracture * dislocation * previous shoulder condition (symptomatic osteoarthritis (gleno-humeral (gh) joint, acromial-clavicular (ac) joint), frozen shoulder, instability, tumor) * malignancy * rheumatic disease * inability to understand swedish * substance abuse
pattern scanning laser pan-retinal photocoagulation in proliferative diabetic retinopathy

Conditions: Diabetic Retinopathy; Lasers; Treatment Outcome

Summary: a randomized study to assess the safety and efficacy of single-session pan-retinal photocoagulation (prp) using pattern scan laser (pascal) in proliferative diabetic retinopathy (pdr) - 1,700 shots vs 2,500 shots


Eligibility criteria:
inclusion criteria: * all treatment-naïve patients with proliferative diabetic retinopathy (pdr) who attended our ophthalmic clinic from 1st december 2012 to 30th november exclusion criteria: * significant media opacity affecting laser uptake (e.g. corneal opacity, mature cataract, dense vitreous haemorrhage) * any pre-existing ocular disorders resulting in visual impairment (e.g. retinal degenerations, maculopathies, primary glaucoma and other optic neuropathies) * those who received previous retinal laser treatment, intravitreal injections or intraocular surgeries * clinically significant macular oedema on clinical examination.
interaction of muscle dystrophy, glucose metabolism and insulin sensitivity

Conditions: Various Forms of Skeletal Muscle Dystrophy

Summary: the aim of this project to characterize systemic and organ-specific (subcutaneous adipose tissue and skeletal muscle) metabolic responses at rest and during standardized, moderate exercise after an oral glucose load in patients with various geneticaly heritable foms of skeletal muscle dystrophies. metabolic responses will be monitored by indirect calorimetry (canopy and/or metabolic chamber at rest and during exercise) and microdialysis (adipose tissue and skeletal muscle at rest) before and after an oral glucose load (75 g).


Eligibility criteria:
inclusion criteria: * controls: healthy, no metabolic, endocrine, neurologic or other diseases * patients: genetically confirmed diagnosis of muscle dystrophy exclusion criteria: * known hemorrhagic diseases / coagulopathies * intake of oral anti-coagulant drugs (control of ptt, inr and platelet count before study entry) * insulin-dependent diabetes mellitus * pregnancy and lactation period * chronic use of non-steroidal antiphlogistics * alcohol and drug abuse * claustrophobia • gleichzeitige teilnahme an einer anderen studie; teilnahme an einer studie vor weniger als zwei monaten unfähigkeit, die mündlichen und schriftlichen informationen zur studie zu verstehen und das schriftliche einverständnis zu geben

Keywords: muscle dystrophy energy metabolism calorimetry metabolic chamber microdialysis exercise
effect of intelligent intervention strategies on self-efficacy and hospital readiness of parents of preterm infants

Conditions: Premature Delivery

Summary: 1. construct intelligent management intervention plan for parents of preterm infants from hospital to family based on the medical and health system suitable for china's national conditions. 2. clinical randomized controlled trials were conducted to verify and evaluate the feasibility and application effect of the intervention program.

based on the previous literature analysis, this study builds an intelligent intervention scheme based on evidence-based methods and theories. finally, we selected the parents of preterm infants in the neonatology department of a third class hospital in shantou to carry out a similar experiment to verify the scheme. with data collected at five critical time points and different interventions provided according to baseline data, the study will reveal significant differences in personalized interventions, self-efficacy at different time points, and hospital discharge readiness among parents of preterm infants in the context of intelligent intervention, showing the relationship between self-efficacy and hospital discharge readiness. this study will fill in the single, traditional model of education and provide new perspectives and methods for future research and clinical practice.

Eligibility criteria:
inclusion criteria: 1. inclusion criteria for premature infants ① gestational age \&lt; 37 weeks；② premature infants admitted to nicu；③ the duration of hospitalization is more than 5 days. 2. inclusion and exclusion criteria of primary caregivers of preterm infants ① preterm infants admitted to neonatology and family caregivers of preterm infants with gestational age \&lt; 37 weeks. ② family members who volunteer to undertake primary care tasks. ③ no mental disorders and can carry out normal language communication； ④ ≥18 years old, proficient in wechat use；⑤ informed consent has been signed. exclusion criteria: 1. exclusion criteria for preterm infants ① intrauterine developmental retardation of preterm infants. ② preterm infants with a history of major surgery. ③ unplanned discharge, transfer, transfer or death of premature infants. 2. exclusion criteria for primary caregivers of preterm infants ① there are recent major mental trauma injuries caused by non-hospitalization factors. ② the caregiver suffers from serious diseases of the heart, brain, lung, kidney and other organs. 3. shedding criteria: caregivers who voluntarily asked to withdraw for various reasons during the study.